Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease

被引:38
|
作者
Petersén, Å [1 ]
Chase, K
Puschban, Z
DiFiglia, M
Brundin, P
Aronin, N
机构
[1] Lund Univ, Wallenberg Neurosci Ctr, BMCAIO, Sect Neuronal Survival, S-22184 Lund, Sweden
[2] Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA USA
[3] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA
关键词
excitotoxicity; striatum; Huntington's disease;
D O I
10.1006/exnr.2002.7885
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
A transgenic mouse model of Huntington's disease (R6/1 and R6/2 lines) expressing exon 1 of the HD gene with 115-150 CAG repeats resisted striatal damage following injection of quinolinic acid and other neurotoxins. We examined whether excitotoxin resistance characterizes mice with mutant huntingtin transgenes. In a new transgenic mouse with 3 kb of mutant human huntingtin cDNA with 18, 46, or 100 CAG repeats, we found no change in susceptibility to intrastriatal injections of the excitotoxin quinolinic acid, compared to wild-type littermates. The new transgenic mice were injected with the same dose of quinolinic acid (30 nmol) as had been the R6 mice. Our findings highlight the importance of studying pathogenetic mechanisms in different transgenic models of a disease. (C) 2002 Elsevier Science (USA).
引用
收藏
页码:297 / 300
页数:4
相关论文
共 50 条
  • [1] Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease
    Shear, DA
    Dong, J
    Gundy, CD
    Haik-Creguer, KL
    Dunbar, GL
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1998, 22 (07): : 1217 - 1240
  • [2] From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease
    Davies, SW
    Turmaine, M
    Cozens, BA
    Raza, AS
    Mahal, A
    Mangiarini, L
    Bates, GP
    PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 1999, 354 (1386) : 971 - 979
  • [3] Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease
    Tattersfield, AS
    Croon, RJ
    Liu, YW
    Kells, AP
    Faull, RLM
    Connor, B
    NEUROSCIENCE, 2004, 127 (02) : 319 - 332
  • [4] Lipoic acid improves survival in transgenic mouse models of Huntington's disease
    Andreassen, OA
    Ferrante, RJ
    Dedeoglu, A
    Beal, MF
    NEUROREPORT, 2001, 12 (15) : 3371 - 3373
  • [5] Dantrolene is neuroprotective in Huntington's disease transgenic mouse model
    Chen, Xi
    Wu, Jun
    Lvovskaya, Svetlana
    Herndon, Emily
    Supnet, Charlene
    Bezprozvanny, Ilya
    MOLECULAR NEURODEGENERATION, 2011, 6
  • [6] Metformin therapy in a transgenic mouse model of Huntington's disease
    Ma, Thong C.
    Buescher, Jessica L.
    Oatis, Benjamin
    Funk, Jason A.
    Nash, Andrew J.
    Carrier, Raeann L.
    Hoyt, Kari R.
    NEUROSCIENCE LETTERS, 2007, 411 (02) : 98 - 103
  • [7] Dantrolene is neuroprotective in Huntington's disease transgenic mouse model
    Xi Chen
    Jun Wu
    Svetlana Lvovskaya
    Emily Herndon
    Charlene Supnet
    Ilya Bezprozvanny
    Molecular Neurodegeneration, 6
  • [8] Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease
    Giampa, Carmela
    Patassini, Stefano
    Borreca, Antonella
    Laurenti, Daunia
    Marullo, Fabrizia
    Bernardi, Giorgio
    Menniti, Frank S.
    Fusco, Francesca R.
    NEUROBIOLOGY OF DISEASE, 2009, 34 (03) : 450 - 456
  • [9] Neuroprotective effects of pyruvate in the quinolinic acid rat model of Huntington's disease
    Ryu, JK
    Kim, SU
    McLarnon, JG
    EXPERIMENTAL NEUROLOGY, 2003, 183 (02) : 700 - 704
  • [10] Behaviour characterization of a model of Huntington's disease in rats, induced by quinolinic acid
    Francis, L
    Cruz, R
    Antúnez, I
    Rosillo, JC
    REVISTA DE NEUROLOGIA, 2000, 30 (11) : 1016 - 1021